The Filing Desk

Insmed

INSM · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

INSM · Last close · November 19, 2026
$144.46
Value Insmed yourself

Insmed's revenue rose 66.7% to $606 million in fiscal 2025. Its operating margin was −205.6%, up from −241.5% a year earlier. Free cash flow was −$968 million. The diluted share count rose 21.3%.

INSMED INC Latest fiscal year ended December 31, 2025 10-K filed February 19, 2026 · 0001104506-26-000009 Updated
Revenue
$606M
66.7%
Operating margin
−205.6%
35.9 pts
Net income
−$1.3B
 
Free cash flow
−$968M
 
Return on equity
−249.3%
 
Market cap
$31.6B
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Insmed lost money in fiscal 2025: a net loss of $1.3 billion.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments7171,1487801,4341,430
Debt incl. finance leases8151,1851,2071,149571
Net debt (negative means net cash)9837427−285−859
Net debt to EBITDA—————
Debt to equity2.0x13.5x—4.0x0.8x
Interest coverage−9.3x−17.3x−8.7x−10.3x−14.9x
Current ratio6.2x6.7x4.1x5.5x3.8x
Quick ratio5.7x6.3x3.8x5.1x3.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Insmed's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Insmed shares on the open market, and 9 insiders sold $133.7 million, $83.2 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 9, 2026David R BrennanDirectorSold25,000$124.00$3.1 millionForm 4
Aug 17, 2026Melvin Md SharokyDirectorSold5,000$127.53$637,650Form 4
Aug 10, 2026Roger AdsettChief Operating OfficerSold239,850$133.27$32.0 millionForm 4
Aug 6, 2026Martina M.D. FlammerChief Medical OfficerSold plan27,173$128.61$3.5 millionForm 4
Jul 23, 2026William LewisChair and CEO, DirectorSold plan10,700$106.06$1.1 millionForm 4
Jul 9, 2026William LewisChair and CEO, DirectorSold plan10,699$117.40$1.3 millionForm 4
Jul 6, 2026Martina M.D. FlammerChief Medical OfficerSold plan12,302$109.98$1.4 millionForm 4
Jun 25, 2026William LewisChair and CEO, DirectorSold plan21,398$103.32$2.2 millionForm 4
Jun 22, 2026Michael Alexander SmithChief Legal OfficerSold plan1,806$95.82$173,051Form 4
Jun 8, 2026William LewisChair and CEO, DirectorSold plan6,515$94.03$612,605Form 4
Jun 5, 2026Martina M.D. FlammerChief Medical OfficerSold plan1,858$103.78$192,823Form 4
Jun 3, 2026William LewisChair and CEO, DirectorSold7,605$102.27$777,763Form 4
The latest 12 of 67 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 94 of 95 of 9
Rule of 40−155.7%−174.9%−92.8%
Altman Z''−8.77−5.47−7.47
Accruals ratio−14.3%−13.7%−15.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassPass
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rosePassFailPass
Revenue rose relative to assetsFailPassPass
F-score3 of 94 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Insmed side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
InsmedFY2566.7%−205.6%−159.6%——5
OPKO HealthFY25−14.9%−19.4%−31.4%−7.0%—4Compare
Axsome TherapeuticsFY2565.5%−26.1%−14.7%——4Compare
HUTCHMED (China)FY25−13.0%−7.1%−14.4%——4Compare
Ultragenyx PharmaceuticalFY2520.2%−79.5%−70.1%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0010136164188245305364606
Revenue growth———1,287.6%20.5%14.6%30.2%24.4%19.2%66.7%
Gross profit007112124144190240278484
Research and development123110145132181273398571598771
Operating income−173−189−307−235−265−375−457−710−878−1,247
Net income−176−193−324−254−294−435−482−750−914−1,277
Diluted EPS (US$)−2.85−2.89−4.22−3.01−3.01−3.88−3.91−5.34−5.57−6.42
Diluted shares (millions)6267778598112123140164199
Cash flow
Cash from operations−147−160−258−251−219−363−400−536−684−935
Capital expenditure4313426710132233
Free cash flow−151−163−271−293−226−371−410−550−706−968
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000070000
Stock-based compensation181826273646587597153
Balance sheet at fiscal year end
Cash and short-term investments1633814954875337171,1487801,4341,430
Debt incl. finance leases55554504714668151,1851,2071,149571
Total assets2384626057427961,2441,6561,3302,0252,265
Total liabilities841013964815208331,5681,6621,7401,526
Shareholders' equity15436120826227641088−332285739
Margins and ratios
Gross margin——75.4%82.3%75.8%76.6%77.5%78.5%76.4%79.7%
Operating margin——−3,124.9%−172.4%−161.3%−199.0%−186.4%−232.5%−241.5%−205.6%
Net margin——−3,297.2%−186.4%−178.9%−230.6%−196.3%−245.6%−251.2%−210.5%
Free cash flow margin——−2,756.2%−214.6%−137.2%−196.6%−167.2%−180.1%−194.1%−159.6%
Rule of 40 (growth + FCF margin)———1,072.9%−116.7%−182.0%−137.0%−155.7%−174.9%−92.8%
Return on capital−272.0%−365.0%−245.1%−91.1%−92.3%−82.6%−114.1%———
Return on equity−75.6%−74.7%−113.9%−108.2%−109.4%−126.7%−193.2%——−249.3%
Return on assets−59.3%−55.0%−60.8%−37.8%−38.2%−42.6%−33.2%−50.2%−54.5%−59.5%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Insmed's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Insmed.